## Docket No. CELL-0102

## **ABSTRACT**

Pyrimidines of formula (1) are described

5

$$Ar N-R^1$$

$$N - R^2$$

$$CN$$

$$(1)$$

wherein Ar is an optionally substituted aromatic or heteroaromatic group;
R¹ is a hydrogen atom or a straight or branched chain alkyl group;
R² is a -X¹-R³ group where X¹ is a direct bond or a linker atom or group, and
0 R³ is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group;
and the salts, solvates, hydrates and N-oxides thereof.

The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states assoicated with angiogenesis.